Geneva (Switzerland) (AFP) - The World Health Organization (WHO) approved clinical trials this Wednesday for two new vaccines against Ebola, in the midst of an epidemic in Africa, where it has killed more than 5,300 people.
First modification: 04/11/2026 - 19:23
A trial began last month using Ervebo, a vaccine approved against the most common Zaire strain of the Ebola virus, but not the Bundibugyo variant, WHO Director-General Tedros Adhanom Ghebreyesus told reporters.
"Today, WHO expert groups recommend adding two vaccine candidates" to these trials, he added.
Both are vaccine candidates against the Bundibugyo strain, which has caused more than 5,300 deaths in the Democratic Republic of the Congo (DRC) in more than five months out of a total of more than 10,400 cases.
One case was detected in Nigeria and nine others, including two deaths, in Kenya in October.
Uganda has recorded 20 cases, one of them fatal, but the WHO has officially declared it Ebola-free.
Among the two new vaccine candidates, one is an adenovirus-based vector, ChAdOx1, developed by the University of Oxford in the United Kingdom with the Serum Institute of India. The other, conceived by the American group Moderna, uses messenger RNA technology.
"Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials and trustful engagement with communities," recalled the WHO director.
© 2026 AFP
The content you requested does not exist or is no longer available.




